Access Download Page
Life Science companies – Reduce the stress of compliance audits and minimise the risks of receiving FDA 483’s & warning letters through utilising a preventative approach. This webinar will give you access to a panel of experts including Robert Lewis FDA consultant, all with one aim – to help Life Science companies reduce the risk of receiving 483’s and warning letters. It will also give you insight into how to handle these warnings with appropriate corrective action. As well as looking at what technology is available to help prevent these warnings.
Common inspection observations
Insight direct from the FDA
Improve Data Integrity
Reduce the risk of receiving 483’s
Panel of Expert Presenters:
Eileen Sullivan-Scully, LZ Lifescience, US Business Development
Siobhan Fleming, LZ Lifescience, EU Business Development
Christian Fortunel, LZ Lifescience, Vice President
Keith Bowen, LZ Lifescience, General Manager
Guest Speaker: Robert Lewis, FDA Consultant, IHL Consulting Group
Robert has been a consultant to US FDA regulated industries since September 2000 when he founded IHL Consulting Group, Inc. During his ten years with the US Food and Drug Administration, Robert served as an Investigator/ Drug/Pharmaceutical Specialist and conducted numerous cGMP and NDA/ ANDA pre-approval inspections at major domestic and international pharmaceutical facilities.